| Literature DB >> 14552767 |
Michael B Tollefson1, Stephen A Kolodziej, Theresa R Fletcher, William F Vernier, Judith A Beaudry, Bradley T Keller, David B Reitz.
Abstract
A series of 5-aryl-3,3-dibutyl-7-(dimethylamino)-1,2-benzothiazepin-4-ol 1,1-dioxides were prepared and were found to inhibit the apical sodium co-dependent bile acid transporter (ASBT) for the potential treatment for hyperlipidemia. Several 1,2-benzothiazepines exhibited low nanomolar in vitro activity. The synthesis and initial in vitro potency data is presented for this novel class of compounds.Entities:
Mesh：
Substances：
Year: 2003 PMID： 14552767 DOI： 10.1016/j.bmcl.2003.08.004
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823